MS Society of Canada to fund multiple sclerosis study
The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation have committed a grant of $3.8m to investigate the complex interplay between degeneration and inflammation in multiple sclerosis (MS).
University of Calgary's Hotchkiss Brain Institute will utilize the funds to study the damage that occurs in MS prior to inflammation.
To date, central nervous system (CNS) damage in MS has been attributed to an autoimmune attack, where inflammation causes the hallmark patches of demyelination.
The primary collaborators of the study include colleagues from the University of Calgary, the University of British Columbia, and Laval University and the VU University in Amsterdam.
University of Calgary Department of Clinical Neurosciences lead researcher Peter Stys said the study hypothesizes that the inflammatory response in MS is caused by an underlying degenerative process rather than the primary cause of injury.
"In other words, an underlying mechanism causes degeneration that prompts the inflammatory process, which in turn causes more degeneration," Stys added.
Related Insight
Suppliers Directory
C3 Research Associates - Clinical Research Development and Management Group
C3 Research Associates is a quality-focused clinical research development and management group supporting innovative biotechnology, medical device and pharmaceutical organizations, stewarding therapeutics from preclinical through phase IV drug development and successful market life cycle.
Contract Research & Services > Contract Research > Suppliers
Paragon Biomedical - Clinical Trial Support
Paragon Biomedical is a global, full-service contract research organization (CRO) providing high quality Phase I-IV clinical trial support to biopharmaceutical and medical device companies, with proven capabilities and expertise in major therapeutic areas.
Contract Research & Services > Contract Research > Suppliers
SCA Cool Logistics - Temperature Controlled Packaging Solutions
SCA Cool Logistics International Group designs, qualifies, manufactures and supplies temperature controlled packaging solutions focusing predominantly, on Pharmaceutical, Biotech, and Clinical Research industries.
Contract Research & Services > Contract Research > Suppliers
DOKUMEDS - Clinical Research and Development Services
DOKUMEDS is full service European Clinical Research Organization providing a comprehensive range of services for clinical research and development to the pharmaceutical, biotechnology and medical devices industry.
Contract Research & Services > Contract Research > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Contract Research Intelligence
Investigator Resources - Canada
Published by Investigator Location Services
Contract Research & Services > Contract Research > White Papers
Biomolecular Screening and ADMET services
Published by Enamine
Contract Research & Services > Contract Research > White Papers
Interview with Dr David Orloff
Published by Medpace
Contract Research & Services > Contract Research > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.